Mitochondrial adaptation decreases drug sensitivity of persistent triple negative breast cancer cells surviving combinatory and sequential chemotherapy.

导出 OA

翻译打印收藏纠错

第一作者： Marie,Winter

第一单位： UMR9020-U1277-CANTHER-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France.

作者： Marie,Winter ^[1] ; Amina,Nait Eldjoudi ^[1] ; Catherine,Guette ^[2] ; Hubert,Hondermarck ^[3] ; Roland P,Bourette ^[1] ; Quentin,Fovez ^[1] ; William,Laine ^[1] ; Bart,Ghesquiere ^[4] ; Eric,Adriaenssens ^[1] ; Jérôme,Kluza ^[1] ; Xuefen,Le Bourhis ^[5]

作者单位： UMR9020-U1277-CANTHER-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France. ^[1] ICO, Inserm, CNRS, Nantes Université, CRCI2NA, Université d'Angers, Angers, France. ^[2] School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW2308, Australia; Hunter Medical Research Institute, University of Newcastle, New Lambton Heights, NSW2305, Australia. ^[3] Metabolomics Expertise Center, Center for Cancer Biology, CCB-VIB, VIB, Leuven, 3000, Belgium; Metabolomics Expertise Center, Department of Oncology, KU Leuven, Leuven, 3000, Belgium. ^[4] UMR9020-U1277-CANTHER-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France. Electronic address: xuefen.le-bourhis@univ-lille.fr. ^[5]

关键词 Chemotherapy Mitochondrial adaptation Persistence Pyruvate Resistance